Reviewing Nu Skin Enterprises (NUS) and biOasis Technologies (BIOAF)

Nu Skin Enterprises (NYSE:NUS) and biOasis Technologies (OTCMKTS:BIOAF) are both consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Nu Skin Enterprises and biOasis Technologies’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nu Skin Enterprises $2.28 billion 1.59 $129.43 million $3.23 20.13
biOasis Technologies $460,000.00 29.00 -$4.12 million N/A N/A

Nu Skin Enterprises has higher revenue and earnings than biOasis Technologies.

Profitability

This table compares Nu Skin Enterprises and biOasis Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nu Skin Enterprises 5.74% 25.67% 11.66%
biOasis Technologies -1,517.77% -407.59% -264.48%

Dividends

Nu Skin Enterprises pays an annual dividend of $1.46 per share and has a dividend yield of 2.2%. biOasis Technologies does not pay a dividend. Nu Skin Enterprises pays out 45.2% of its earnings in the form of a dividend. Nu Skin Enterprises has increased its dividend for 17 consecutive years.

Institutional & Insider Ownership

76.5% of Nu Skin Enterprises shares are owned by institutional investors. 5.2% of Nu Skin Enterprises shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Nu Skin Enterprises has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, biOasis Technologies has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Nu Skin Enterprises and biOasis Technologies, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nu Skin Enterprises 0 2 4 0 2.67
biOasis Technologies 0 0 0 0 N/A

Nu Skin Enterprises presently has a consensus price target of $84.83, indicating a potential upside of 30.47%. Given Nu Skin Enterprises’ higher probable upside, equities research analysts clearly believe Nu Skin Enterprises is more favorable than biOasis Technologies.

Summary

Nu Skin Enterprises beats biOasis Technologies on 12 of the 14 factors compared between the two stocks.

About Nu Skin Enterprises

Nu Skin Enterprises, Inc. develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, and LifePak nutritional supplements, as well as other anti-aging nutritional solutions and weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates walk-in centers and pick-up locations; and retail stores and service centers in Mainland China. The company sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.

About biOasis Technologies

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders in the areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. Bioasis Technologies Inc. has a collaborative research agreement with CQDM and Brain Canada to perform research on the delivery of therapeutic compounds across the blood-brain barrier; and a strategic collaboration with BIOAGILYTIX for the development and validation of bioanalytical methods to support the xB3 TM-001 program. It also has a strategic collaboration with WuXi Biologics (Hong Kong) Limited for the development and manufacturing of xB3-001 to treat cancer. The company was incorporated in 2006 and is headquartered in Guilford, Connecticut.

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply